Thalia Therapeutics PLC Sustainability Reports

Thalia Therapeutics plc is a biotechnology company focused on developing innovative RNA therapeutics and novel delivery systems. The company develops a proprietary delivery platform named Nuvec to target unmet needs in oncology and cardiovascular treatments.

Sector: Professional & technical services

Country: United Kingdom

Exchange: London Stock Exchange (AIM)

LEI: 213800I841D2RKMFK955

FIGI: BBG001SBT9Q3

12 reports from 2014 to 2025

• Thalia Therapeutics PLC 2025 Annual Report and Consolidated Financial Statements
• Thalia Therapeutics PLC 2024 Annual Report and Consolidated Financial Statements
• Thalia Therapeutics PLC 2023 Annual Report and Consolidated Financial Statements
• Thalia Therapeutics PLC 2022 Annual Report and Consolidated Financial Statements
• Thalia Therapeutics PLC 2021 Annual Report and Consolidated Financial Statements